Integra LifeSciences Holdings Corporation presented updates at the 44th Annual J.P. Morgan Healthcare Conference, highlighting its performance and strategic direction. The company reported $1.6 billion in revenue and an $89 million operating cash flow for the trailing twelve months ended September 30, 2025, with adjusted gross margin at 62.8% and adjusted EBITDA margin at 19%. Integra emphasized its leadership in the $9 billion global market for neurosurgery, ENT, and tissue technologies, with a focus on portfolio prioritization, supply chain resiliency, and innovation in both organic and inorganic product development. The company is positioned to benefit from changing reimbursement policies, particularly in the skin substitutes segment, and continues to invest in clinical evidence generation to drive growth. Key products mentioned include PriMatrix®, SurgiMend®, and Durepair®. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Integra LifeSciences Holdings Corporation published the original content used to generate this news brief on January 14, 2026, and is solely responsible for the information contained therein.